Dateline City:
KENILWORTH, N.J.
Data Comparing KEYTRUDA to Chemotherapy Shows Continued Benefit with Follow-Up Beyond 2.5 Years in Patients with Ipilimumab-Refractory Advanced Melanoma
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced findings from the final overall survival (OS) analysis
from the KEYNOTE-002 study investigating the use of KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, compared to
investigator-choice chemotherapy with a crossover to KEYTRUDA design, in
patients with ipilimumab-refractory advanced melanoma.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more